Novo Nordisk Spends $11 Billion to Make More Weight Loss Drugs

GALWAY, IRELAND--February 15, 2024--Written by Martin Lynch, European News Editor for Industrial Info (Galway, Ireland)--Danish pharmaceutical company Novo Nordisk is capitalizing on the unprecedented success of its diabetes and weight loss drugs by agreeing to pay US$11 billion to acquire three new production plants in Europe and the U.S.

Within this article: Details purchase of three plants from Catalent to boost global supplies of diabetes and anti-obesity products Ozempic and Wegovy, locations, state of the market, related investments